8-K filings and company releases
Company news
3 articles on AbCellera Biologics.
Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first. Each one links to the filing or release it was written from.Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first.
ABCL articles
Newest first, 25 to a page- Form 8-K
Aug 13, 2026 · Form 8-K
AbCellera Biologics prices $200 million offering of common shares and pre-funded warrants
AbCellera Biologics said gross proceeds are expected to be approximately $200 million, before underwriting discounts and offering expenses.
- Form 8-K
Jul 6, 2026 · Form 8-K
AbCellera Biologics appoints Lynn Seely to its board of directors
Seely is president and CEO of Lyell Immunopharma Inc. and was previously CEO of Myovant Sciences Inc.
- Form 8-K
Jun 12, 2026 · Form 8-K
AbCellera Biologics shareholders elect two Class III directors
The meeting covered 305,264,947 common shares outstanding and entitled to vote as of the April 15, 2026 record date.
How these are written
- The source: the company's own 8-K filing or press release, linked from every article. What the company says is attributed to the company.
- The checks: each article is written by GetSignal with AI and checked against its source before it is shown.
- The date: the day the company filed the 8-K or published the release.
- Not investment advice. An article reports what the company disclosed; it is not a view on the stock.
